PlainPharmaWatch

CMS Open Payments · Program Year 2024

Stemline Therapeutics Inc.

Stemline Therapeutics Inc. reported $4,740,819.55 in payments to 6,314 physicians and teaching hospitals across 6,720 transactions.

See the rankings → How this is sourced
$4.7M
Total payments
6,720
Transactions
6,314
Recipients
−$425.2K
General Payments vs PY2023

Stemline Therapeutics Inc. reported $4,740,819.55 in payments to 6,314 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #286 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $750.84 per recipient across 6 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Stemline Therapeutics Inc. pairs top-quartile payment volume with an unusually diversified payment pattern across a wide recipient base.

#286
of 1,925 companies
0.0%
of all US industry payments
0.1%
paid to its single top recipient
6
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Stemline Therapeutics Inc.'s CMS-reported General Payments decreased by $425.2K (−20.5%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: STEMLINE THERAPEUTICS INC.PY2023: STEMLINE THERAPEUTICS INC.PY2024: Stemline Therapeutics Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$2.1MPY2024$1.6M
PY2023
$2,074,879.36
PY2024
$1,649,682.93

How Stemline Therapeutics Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Stemline Therapeutics Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$4,740,820 Top 15% higher than 85% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). This entry sits in this band. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Stemline Therapeutics Inc.

In Program Year 2024, Stemline Therapeutics Inc. reported $4,740,819.55 in payments to 6,314 physicians and teaching hospitals across 6,720 individual transactions, an average of $705.48 per transaction and $750.84 per recipient. That total places Stemline Therapeutics Inc. at rank #286 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

245 transactions worth $722.7K make "Compensation for Services Other Than Consulting" the top general-payment category in the 6-category breakdown below, 15.2% of the reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 6 types of general payments, Stemline Therapeutics Inc.'s largest category was "Compensation for Services Other Than Consulting" at $722.7K - 15.2% of the company's reported total.

How Stemline Therapeutics Inc. divides its payments

Ranked by total dollars reported per category

1. Compensation for Services…$722.7K2. Consulting Fee$604.5K3. Food and Beverage$179.8K4. Travel and Lodging$140.2K5. Honoraria$2.3K6. Education$91.03
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $722.7K 245
Consulting Fee $604.5K 153
Food and Beverage $179.8K 5,602
Travel and Lodging $140.2K 285
Honoraria $2.3K 12
Education $91.03 17

Recipient Concentration in General Payments

The five largest recipient relationships account for $509,059.68 (30.9%) of $1,649,682.93 in this company's General Payments records across 3,689 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Stemline Therapeutics Inc.

The five named recipients with the highest reported General Payments from this company

Samir Khleif$141.3KAnne P Odea$136.2KEnrique Garcia$117.7KFengting Yan$58.9KVijayakrishna Gadi$55.1K
  1. 1

    Samir Khleif

    $141,250.00 across 1 reported transactions

  2. 2

    Anne P Odea

    $136,175.95 across 86 reported transactions

  3. 3

    Enrique Garcia

    $117,700.00 across 4 reported transactions

  4. 4

    Fengting Yan

    $58,864.45 across 45 reported transactions

  5. 5

    Vijayakrishna Gadi

    $55,069.28 across 33 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $705.48. Average per recipient: $750.84.

Total Amount

$4,740,819.55

Avg per Transaction

$705.48

Avg per Recipient

$750.84

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Stemline Therapeutics Inc. Share

0.0%

#286 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Stemline Therapeutics Inc.

Novocure GmbH

$4.8M 7 recipients

TriSalus Life Sciences, Inc.

$4.8M 2,429 recipients

Progenics Pharmaceuticals, Inc.

$4.8M 6,457 recipients

Inspire Medical Systems, Inc.

$4.8M 51,283 recipients

InSightec,LTD

$4.9M 2 recipients

Blustone Synergy, LLC

$4.9M 0 recipients

Frequently Asked Questions

How much did Stemline Therapeutics Inc. pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $4,740,819.55 from Stemline Therapeutics Inc. to physicians and hospitals across 6,720 transactions - 0.0% of all industry payments reported that year.
How many physicians received payments from Stemline Therapeutics Inc.? ▾
Averaging $750.84 per recipient, Stemline Therapeutics Inc.'s 2024 payments reached 6,314 physicians and teaching hospitals.
What types of payments did Stemline Therapeutics Inc. make? ▾
6 categories of general payment make up Stemline Therapeutics Inc.'s reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Compensation for Services Other Than Consulting" at $722.7K, representing 15.2% of the company's reported total.
How does Stemline Therapeutics Inc. rank among pharmaceutical companies? ▾
Stemline Therapeutics Inc. ranks #286 out of 1,925 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from Stemline Therapeutics Inc.? ▾
In 2024, Stemline Therapeutics Inc. averaged $705.48 per transaction across 6,720 transactions to 6,314 recipients.
Where does the payment data for Stemline Therapeutics Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Stemline Therapeutics Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.